Wright Medical Group, Inc. Receives FDA Approval To Market CONSERVE(R) Plus Total Hip Resurfacing System

Wright Medical Group, Inc. (NASDAQ: WMGI), a global orthopaedic medical device company, announced that the United States Food and Drug Administration (FDA) has given approval to the Company to market its original CONSERVE® Plus Total Hip Resurfacing System.

Original post: 
Wright Medical Group, Inc. Receives FDA Approval To Market CONSERVE(R) Plus Total Hip Resurfacing System

Related posts:

1. Amneal Receives FDA Approval For Nizatidine Oral Solution, The First Generic Oral Solution For Axid(R) In The Market Amneal Pharmaceuticals is pleased to announce that it has received U.S. FDA approval to manufacture Nizatidine Oral Solution in the 15 mg/mL strength effective November 18, 2009. It is an...
2. SafeStitch Medical, Inc. Receives FDA Clearance To Market The AMID StaplerTM For Hernia Repairs SafeStitch Medical, Inc. (OTCBB:SFES) announced that it has received 510(k) clearance from the U.S. Food and Drug Administration ("FDA") to market its AMID StaplerTM in the U.S. with the intended...
3. Mylan Receives Tentative FDA Approval Under PEPFAR For Matrix Laboratories’ New Drug Application (NDA) For Efavirenz Tablets Mylan Inc. (Nasdaq: MYL) announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS...
4. Pfizer Receives FDA Approval For Geodon(R) (Ziprasidone HCI) Capsules For The Adjunctive Maintenance Treatment Of Bipolar Disorder In Adults Pfizer announced that the U.S. Food and Drug Administration (FDA) has approved Geodon® (ziprasidone HCI) Capsules for maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate...
5. Tripep Receives Approval For Expanding The ChronVac-C(R) Study With One More Vaccination Tripep (STO:TPEP) received the approval from the Swedish Medical Products Agency and the local ethical committee to give three patients in the highest dose group in the ChronVac-C® study one...
6. DGIMED Receives FDA Clearance On IM Nail System DGIMED ORTHO, Inc. announced that the company has received notification of clearance on its 510(k) submission for the Company's proprietary Drill and Intramedullary (IM) Nail system. "This timely notification keeps...
7. Mylan Receives Approval For Generic Version Of Antiepileptic Keppra® 1000 Mg Mylan Inc. (NASDAQ: MYL) announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for...
8. Santarus Announces FDA Approval Of Schering-Plough HealthCare Products’ ZEGERID OTC Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Schering-Plough HealthCare Products, Inc.'s, New Drug Application (NDA) for ZEGERID...
9. Endologix Receives IDE Approval For Fully Percutaneous Approach To EVAR Endologix, Inc. ...
10. Dendreon Receives FDA Acknowledgement Of Complete Response Dendreon Corporation (Nasdaq: DNDN) announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete...
11. Abbott Seeks FDA Approval Of New Dosage Strengths Of SIMCOR(R) (niacin Extended-release/simvastatin) Abbott (NYSE: ABT) has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for two new dosage strengths of SIMCOR®, a cholesterol medication. SIMCOR...
12. Novartis Receives Regulatory Approval In Germany For Celtura®, A Cell Culture-based Influenza A(H1N1) Pandemic Vaccine Novartis announced that it received approval from the German regulatory authorities for its adjuvanted cell culture-based Influenza A(H1N1) 2009 monovalent vaccine, Celtura®. Novartis continues to pursue registration in other major...
13. Merck KGaA Receives Refuse To File Letter From FDA On Cladribine Tablets New Drug Application Merck KGaA announced that its US affiliate received a refuse to file letter from the US Food and Drug Administration (FDA) on the New Drug Application (NDA) for Cladribine Tablets,...
14. The Medicines Company Receives European Approval For Angiox(R) (Bivalirudin) For Use In Heart Attack Patients Undergoing Emergency Heart Procedures The Medicines Company (NASDAQ: MDCO) announced today that it has received European approval for the use of Angiox® (bivalirudin) as an anticoagulant in patients with heart attacks (so-called ST-segment elevation...
15. Neuralstem Receives Approval To Commence First ALS Stem Cell Trial At Emory ALS Center Neuralstem, Inc. (NYSE Amex: CUR) announced that its Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells has been approved...

« House Health Bill Votes Stir Political Action, Ads Phadia Introduces New Food Allergy Diagnostic Tools To Meet The Needs Of Allergists »